JP2016510327A - ｐ５３再活性化のためのオリゴオキソピペラジン - Google Patents

ｐ５３再活性化のためのオリゴオキソピペラジン Download PDF

Info

Publication number
JP2016510327A
JP2016510327A JP2015553892A JP2015553892A JP2016510327A JP 2016510327 A JP2016510327 A JP 2016510327A JP 2015553892 A JP2015553892 A JP 2015553892A JP 2015553892 A JP2015553892 A JP 2015553892A JP 2016510327 A JP2016510327 A JP 2016510327A
Authority
JP
Japan
Prior art keywords
aryl
alkyl
arylalkyl
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015553892A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510327A5 (cg-RX-API-DMAC7.html
Inventor
パラムジット エス． アローラ
パラムジット エス． アローラ
キンティン パン
キンティン パン
アナ マップ
アナ マップ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Original Assignee
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU filed Critical New York University NYU
Publication of JP2016510327A publication Critical patent/JP2016510327A/ja
Publication of JP2016510327A5 publication Critical patent/JP2016510327A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015553892A 2013-01-19 2014-01-21 ｐ５３再活性化のためのオリゴオキソピペラジン Pending JP2016510327A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361754575P 2013-01-19 2013-01-19
US61/754,575 2013-01-19
PCT/US2014/012337 WO2014113794A2 (en) 2013-01-19 2014-01-21 Oligooxopiperazines for p53 reactivation

Publications (2)

Publication Number Publication Date
JP2016510327A true JP2016510327A (ja) 2016-04-07
JP2016510327A5 JP2016510327A5 (cg-RX-API-DMAC7.html) 2017-02-23

Family

ID=51207874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015553892A Pending JP2016510327A (ja) 2013-01-19 2014-01-21 ｐ５３再活性化のためのオリゴオキソピペラジン

Country Status (7)

Country Link
US (1) US9695153B2 (cg-RX-API-DMAC7.html)
EP (1) EP2945631A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016510327A (cg-RX-API-DMAC7.html)
CN (1) CN105246481A (cg-RX-API-DMAC7.html)
AU (1) AU2014207311A1 (cg-RX-API-DMAC7.html)
CA (1) CA2898329A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014113794A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015179547A2 (en) * 2014-05-21 2015-11-26 New York University Oxopiperazine helix mimetics for control of hypoxia-inducible gene expression
JOP20170053B1 (ar) 2016-03-02 2021-08-17 Eisai Randd Man Co Ltd مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
MA51139A (fr) 2017-12-15 2020-10-21 Inthera Bioscience AG Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012021144A1 (en) * 2010-08-12 2012-02-16 New York University Oligooxopiperazines and methods of making and using them
JP2015508779A (ja) * 2012-02-16 2015-03-23 ニューヨーク・ユニバーシティ 低酸素状態で誘導可能な遺伝子発現の、オリゴオキソピペラジン非ペプチド性へリックス模倣体による制御

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3542230A1 (de) 1985-11-29 1987-06-04 Bayer Ag Verfahren zur herstellung von oligomeren und telechelen mit carboxy-piperazin-einheiten und neue oligomere und telechele des poly(carboxypiperazins)
GB9022790D0 (en) 1990-10-19 1990-12-05 Wyeth John & Brother Ltd Piperazine derivatives
BR9510360A (pt) 1994-12-23 1997-12-23 Thomae Gmbh Dr K Derivados de piperazina medicamentos contendo esses compostos sua aplicação e processo para sua preparação
FR2803594B1 (fr) 2000-01-11 2002-07-19 Centre Nat Rech Scient Oligomeres de mimes contraints non peptidiques de dipeptides ou de tripeptides, et leurs utilisations
KR100464261B1 (ko) 2002-01-24 2005-01-03 주식회사 파나진 Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
US6841675B1 (en) 2002-06-13 2005-01-11 The Regents Of The University Of California Piperazine-based nucleic acid analogs
KR100962301B1 (ko) 2006-11-03 2010-06-11 재단법인서울대학교산학협력재단 자궁경부암을 위한 치료용 조성물
US20090197895A1 (en) 2008-01-31 2009-08-06 The Scripps Research Institute Oxazole-pyrrole-piperazine alpha-helix mimetic
BRPI0919414A2 (pt) 2008-09-18 2017-07-11 Univ New York Inibição da interação entre hif-1alfa e p300/cbp com hélices à base de substituintes de ligação de hidrogênio

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012021144A1 (en) * 2010-08-12 2012-02-16 New York University Oligooxopiperazines and methods of making and using them
JP2015508779A (ja) * 2012-02-16 2015-03-23 ニューヨーク・ユニバーシティ 低酸素状態で誘導可能な遺伝子発現の、オリゴオキソピペラジン非ペプチド性へリックス模倣体による制御

Also Published As

Publication number Publication date
CN105246481A (zh) 2016-01-13
AU2014207311A1 (en) 2015-08-20
EP2945631A4 (en) 2016-06-29
WO2014113794A2 (en) 2014-07-24
CA2898329A1 (en) 2014-07-24
WO2014113794A3 (en) 2014-09-12
EP2945631A2 (en) 2015-11-25
US20140205655A1 (en) 2014-07-24
US9695153B2 (en) 2017-07-04

Similar Documents

Publication Publication Date Title
US9605026B2 (en) Hydrogen-bond surrogate peptides and peptidomimetics for p53 reactivation
US20250235432A1 (en) Methods of treating cancers
US12383555B2 (en) Methods of treating cancers
TW202136252A (zh) 化合物及其用途
CN115867314A (zh) 治疗癌症的方法
JP2021506973A (ja) がん治療のための１−（ピペリジノカルボニルメチル）−２−オキソピペラジン誘導体
EP3732301A1 (en) Methods of cancer treatment using an atr inhibitor
ES2991090T3 (es) Inhibidores de KDM4
JP2020536096A (ja) 腫瘍成長を阻害するための材料および方法
US9695153B2 (en) Oligooxopiperazines for p53 reactivation
JP2016539188A (ja) 新規カベオリンモジュレーターを使用する自己免疫および／または炎症疾患の治療
Bordan et al. PDZ-binding kinase, a novel regulator of vascular remodeling in pulmonary arterial hypertension
US20240307325A1 (en) Compounds, compositions, and methods for treating or ameliorating nonalcoholic fatty liver disease and related diseases or disorders
JP6986263B2 (ja) 抗ウイルス薬
US20240226036A1 (en) 2-s rimantadine and 2-r rimantadine for treating cancer
CN111108083B (zh) 氨基亚甲基环己烷1,3-二酮化合物的用途
CN121079296A (zh) α-v-β-8整合素抑制剂及其用途
US11427543B2 (en) Compounds for targeting cancer stem cells
CN111139299B (zh) Josd2蛋白在制备治疗恶性肿瘤药物中的应用
US20240124610A1 (en) Methods for treating her2-negative or her2-low cancer
HK40080608A (en) Compounds and uses thereof
KR20250021325A (ko) 유전적 동인을 조절하기 위한 조성물 및 방법
JP2025527370A (ja) ヒストンメチルトランスフェラーゼ核局在化の新規阻害剤
WO2017159739A1 (ja) 抗がん剤
Almatrrouk Investigation of Novel Cytostatic Therapy for HCV Induced Liver Cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180319